Obinutuzumab for refractory minimal change disease in obese patients: a case series

1

Obinutuzumab, a type II anti-CD20 monoclonal antibody, shows promise for obese patients with refractory minimal change disease (MCD) unresponsive to rituximab.
2

Two obese patients with biopsy-confirmed MCD achieved complete remission after receiving obinutuzumab following inadequate responses to other treatments.
3

Patient 1 maintained remission for over 26 months post-obinutuzumab, with complete B-cell depletion observed during follow-up.
4

Patient 2 experienced a relapse after stopping immunosuppressants but regained remission with a subsequent dose of obinutuzumab.
5

These cases suggest that obesity may affect treatment response in MCD, highlighting the need for tailored therapeutic strategies.

1